Citius Pharmaceuticals has concluded the merger of its wholly-owned oncology subsidiary with TenX Keane Acquisition, forming the new entity Citius Oncology. The merger, which was announced in October 2023, is set to take the newly combined company public, trading on the stock exchange under the ticker symbol CTOR. The gold standard of business intelligence.
Following closure, all shares of Citius Pharma’s subsidiary were converted into rights to receive common stock of Citius Oncology, with Citius Pharma retaining 90% ownership of the new public company. Additionally, Citius Oncology will assume an existing 12.75 million options.
The company will continue to operate under a shared services agreement with Citius Pharma. Citius Oncology will focus on developing and commercialising new targeted oncology therapies. Access the most comprehensive Company Profiles on the market, powered by GlobalData.
Save hours of research. Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles.
However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form Its primary asset, LYMPHIR, recently received US Food and Drug Administration approval for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL) who have undergone a minimum of one previous systemic therapy. Management of the company has estimated the.